This page is updated frequently with new Hypertension-related patent applications.
160+ Hypertension-related patent PDFs
|Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses|
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.
|Use of modified vasoactive intestinal peptides in the treatment of hypertension|
The present invention is based on the discovery that a vip having a binding preference for vpac2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided..
Phasebio Pharmaceuticals, Inc.
|Serca2 therapeutic compositions and methods of use|
The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (aav)-serca2 composition to a subject in need thereof.. .
Icahn School Of Medicine At Mount Sinai
|Ablation targeting nerves in or near the inferior vena cava and/or abdominal aorta for treatment of hypertension|
A method for the treatment of a patient for the purpose of lowering blood pressure and/or treating other medical conditions such as cardiac arrhythmias. A catheter having an ablation element is placed inside the body of a patient and is directed to a targeted location either on in the abdominal aorta where the right or left renal arteries branch from the aorta at or near the superior junction or ostia or on the inside of the inferior vena cava near the junction with the right renal vein or in the left renal vein at a position spatially near where the left renal artery branches from the abdominal aorta.
Biosense Webster (israel), Ltd.
|Methods for therapeutic renal neuromodulation|
Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.
|Methods and materials for treating elevated sympathetic nerve activity conditions|
This document provides methods and materials involved in treating hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease). For example, methods and materials involved in administering one or more sympatholytic agents to a patient to identify the patient as having an elevated baseline level of sympathetic nerve activity and treating the identified patient with a sympatholytic therapy to reduce the symptoms of hypertension (e.g., resistant hypertension), heart failure (e.g., congestive heart failure), or kidney disease (e.g., chronic kidney disease) are provided..
Mayo Foundation For Medical Education And Research
|Heteroaromatic compounds and their use as dopamine d1 ligands|
And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .
|Substituted pyridazines as prostacyclin receptor modulators|
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.
|Method of reducing renal hypertension and computer-readable medium|
A method of reducing renal hypertension applied for electrically stimulating a target zone of an organism having a symptom of renal hypertension by using an electronic stimulation device. The electronic stimulation device comprises at least one electronic stimulation unit.
Gimer Medical Co., Ltd.
|Prostamide-containing intraocular implants and methods of use thereof|
Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle.
Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions
Methods and compounds for research and treatment of portal hypertension. The use of racemic or non-racemic mixtures of furopyridine isomers to stimulate enos function in sinusoidal endothelial cells and to increase no production in both normal sinusoidal endothelial cells and injured endothelial cells..
Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
The disclosed subject matter provides certain n-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition.
The Johns Hopkins University
Prostacyclin compounds, compositions and methods of use thereof
Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear c5-c18 alkyl, branched c5-c18 alkyl, linear c2-c18 alkenyl, branched c3-c18 alkenyl, aryl, aryl-c1-c18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described.
Novel formulations and methods
Nanoparticles comprising vip and their use in treating, e.g., pulmonary hypertension. Such nanoparticles provide improved delivery of vip and allow for acute treatment and optionally for sustained release of vip in a patient..
Avant Garde Therapeutics And Technologies, Llc
Intraocular pressure modification
Assemblies and methods for modifying an intraocular pressure of a patient's one or both eyes are disclosed. The assemblies and methods can be used to treat, inhibit, or prevent ocular conditions such as glaucoma, high intraocular pressure, optic disc edema, idiopathic intracranial hypertension, zero-gravity induced papilledema, and other optic pressure related conditions.
Dr. John Berdahl
Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaecutical use
The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (ndga) compounds and butane bridge modified tetra-o-substituted ndga compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as hiv infection, hpv infection, or hsv infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.. .
Erimos Pharmaceuticals Llc
Inhibitors of the renal outer medullary potassium channel
The present invention provides compounds of formula (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.
Method of treating pulmonary arterial hypertension
The present invention is concerned with the treatment of pulmonary arterial hypertension (pah) by administering paliperidone. The instant invention further relates to use of a pharmaceutical composition comprising paliperidone, for the treatment of pah..
Cipla (uk) Limited
Device and treatment of retinal detachment and other maladies of the eye
The present invention includes a device and method for treatment of retinal detachment, ocular hypertension and glaucoma, and increasing an amplitude of accommodation. The device includes a tapered, mesh tube that within a sclera, expands to deform the sclera, and when placed within the posterior sclera for the treatment of a retinal tear, the device expands deforming the sclera so that the retinal pigment epithelium comes in contact with the retinal tear to seal the tear.
And related methods for treating a person having a disorder characterized by undesirable 5-ht2b receptor signaling, such as migraine, irritable bowel syndrome (ibs), pulmonary arterial hypertension (pah), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (gi) tract disorders.. .
Dietary compositions for reducing blood glucose levels and for weight management
The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.
Carrier status of annexin a5 m2 haplotype and obstetric risks
The present invention relates to determining the carrier status of annexin a5 m2 haplotype of parents (both male and female) prior to and/or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (rpl), infertility, miscarriage, in vitro fertilization (ivf) failure, iui failure, implantation failure, foetal growth restriction (fgr), small for gestational age (sga) newborn, intra-uterine foetal death (iufd), gestational hypertension (gh), pre-eclampsia (pe) and/or venous thromboembolism (vte). Once m2 carrier status is determined, methods of intervention, including administration of low molecular weight heparin (lmwh) and/or other anti-coagulants can be administered either prior to and/or after pregnancy.
Ihg Pharmaco Limited
Compositions and methods of inhibiting histone deacetylases
The present invention provides compositions and methods for treating pulmonary hypertension. In one aspect, a method is included for increasing myocyte enhancer factor 2 (mef2) activity in an endothelial cell comprising exposing the cell to a class iia histone deacetylase inhibitor.
The present invention relates to methods for assessing or obtaining an indication of vascular pressure associated with organs or visceral tissues of the body by using mri imaging methods. The invention particularly relates to methods for assessing or obtaining an indication of portal hypertension using magnetic resonance t1, or t1 and t2* relaxometry, and t1, t2 and/or t2* mapping of the liver or spleen..
Oxford University Innovation Limited
Benzimidazole derivatives and preparation process and pharmaceutical uses thereof
The invention belongs to the technical field of pharmaceutical chemistry, and particularly pertains to benzimidazole derivatives, and preparation process and pharmaceutical uses thereof. Benzimidazole derivatives include ligustrazine and no donor derivatives.
Wuhan Qr Pharmaceuticals Co., Ltd
Potassium-binding agents for treating hypertension and hyperkalemia
The present invention generally relates to methods of treating hypertension (htn) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (ckd) or type ii diabetes mellitus (t2dm). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from ckd, t2dm or htn and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (raas) agent.
Drug therapy for preventing or treating glaucoma
There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma..
Kowa Co., Ltd.
Administration of iloprost as aerosol bolus
The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy.
Pharmaceutical administration system for the transdermal application of vardenafil
A pharmaceutical administration system for the transdermal application of at least one active agent includes vardenafil and/or a pharmaceutically acceptable salt thereof as the active agent and a pharmaceutically acceptable carrier providing a solution of the at least one active agent in the administration system. Another active agent may be testosterone.
Lipp Life Sciences Llc
Congestive Heart Failure
Follow us on Twitter
This listing is a sample listing of patent applications related to Hypertension for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Hypertension with additional patents listed. Browse our RSS directory or Search for other possible listings.